Instructions for Phezam (Piracetam, Cinnarizine) 60 capsules
Release Form:
caps. 400 mg+25 mg: 30 or 60 pcs.
Description:
Capsules are solid gelatin, size 0, cylindrical, white; Conglomerates are a powder-like mixture of white to almost white color, and conglomerates are allowed which, when pressed with a glass wand, easily turn into powder.
1 caps.
piracetes 400 mg
zinnarisin 25 mg
Auxiliary substances: lactose monohydrate - 55 mg, silicon coloidal dioxide - 15 mg, magnesium stearate - 5 mg.
Shell composition: Titanium dioxide - 2%, gelatin - 98%.
10 pcs. - blister (3) - cardboard× packs.
10 pcs. - blister (6) - cardboard× packs.
Packages of cardboard, which can be additionally marked with protective stickers.
ATX codes
N06BX Other psychostimulators and nootropic drugs Phezam
Pharmacological groups / Group membership:
A drug Phezam that improves blood circulation and metabolism in the brain
Active substance:
piracetam
cinnarizine
Pharmaco Therapeutic Group:
Nootropic agent
Storage conditions
The drug Phezam should be stored in a place inaccessible to children at a temperature not higher than 25 ° C.
Shelf life
Shelf life is 3 years. Do not apply after expiration date specified on package
Pharmaceuticals:
A combination drug Phezam with a pronounced antihypoxic, nootropic, and vasodoroexpanding effect. The components mutually have the potential to reduce the resistance of the brain's blood vessels and contribute to their blood flow.
Piracetes activate metabolic processes in the brain by strengthening energy and protein exchange, accelerating cell utilization of glucose and increasing its resistance to hypoxia; improves interneuronal transmission to the NSC, improves regional blood flow in the isemized zone.
Cinnarisin is a selective blockage of slow calcium channels and an antagonist of histamine H1 receptors. It is established that zinnaryzin inhibits the entry of calcium ions into cells and reduces their content in the depot of plaszmolemma, reduces the tone of smooth arteriol musculature, reduces their reaction to biogenic vascular substances ( catecholamines, angiotensin and vasopressin). It has a vasodilating effect (especially with regard to brain vessels, increasing the antihypoxic action of piracetam) without having a significant effect on AD. It exhibits moderate antihistamine activity, reduces the excitability of the vestibular laser apparatus, Tones the sympathetic nervous system. Improves the elasticity of erythrocyte membranes, their ability to deform, reduces blood viscosity.
Testimony:
- Insufficiency of brain blood circulation (atherosclerosis of brain vessels, recovery period of ischemic and hemorrhagic strokes, cranial and brain injuries, encephalopathy of various genes);
- intoxication;
- Diseases of the CNS, accompanied by the decrease of intellectual and mnastic functions (memory disturbances, attention, moods);
- post-brain trauma;
- organo-psychosis syndrome, with the predominance of the signs of asthenia and apamine;
- asthenic syndrome of psychogenic genesis;
- labyrinthopathy (dizziness, tinnitus, nausea, vomiting, nistagm);
- Menier syndrome;
- prevention of migraines and kinetos;
- In the complex therapy of low learning in children with psycho-organic syndrome.
Special Instructions:
The drug Phezam should be carefully administered to persons with liver and/or kidney diseases. In cases of mild and moderate kidney failure (especially if the CC is less than 60 ml/min), the therapeutic dose should be reduced or the interval between the treatments increased. In persons with liver impairment, control of liver enzymes is necessary.
The use of alcohol during treatment should be avoided.
A drug can cause a false positive reaction when controlling doping drugs Phezam at athletes.
The drugPhezam increases the activity of thyroid hormones and can cause tremor and anxiety.
Impact on the ability to drive vehicles and mechanisms
Care should be taken when driving vehicles and working with machines and equipment during treatment, since cynnarysine may cause sleepiness at the beginning of treatment.
Application for kidney disorders:
The use of the drug Phezam for severe kidney failure (CC <20 ml/min) is contraindicated.
Carefully prescribe a drug Phezam for kidney disorders.
Application for liver disorders
The use of the drug in severe liver failure is contraindicated.
Careful prescription of the drug Phezam in case of liver disorders.
Application of children
The use of the drug Phezam in children under 5 years of age is contraindicated.
Medicinal interaction:
With the simultaneous intake of drugs Phezam that oppress the central nervous system, tricyclic antidepressants and alcohol increases the sedative effect.
The drug Phezam potentiates the action of nootropic and antihypertensive drugs.
Vasodilators enhance the effect of the drug Phezam.
Improves the tolerance of antipsychotic drugs Phezam and tricyclic antidepressants.
It is possible to increase the action of oral anticoagulants.
Nozology (ICD codes)
Personal disorders and behaviors caused by brain disease, damage or dysfunction
Non-vegetation
Mental backwardness unspecified
Specific learning disorders
Migren
Toxic encephalopathy
Encephalopathy Unspecified
Menera's Disease
Labyrinth dysfunction
Other specified internal ear diseases
Brain Infarction
Cerebral atherosclerosis
Hypertensive encephalopathy
Effects of cerebrovascular diseases
Malnutrition and fatigue
Intracranial trauma
Driving
Head injury effects
Recomended 5/5.
